renal cell carcinoma

Summary

Summary: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Top Publications

  1. ncbi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
  2. pmc Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:3584-90. 2009
  3. ncbi Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
  4. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
  5. ncbi Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
  6. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
  7. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
  8. ncbi Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma
    Hanne Krogh Jensen
    Department of Oncology, Aarhus University Hospital, 8000 Aarhus C, Denmark
    J Clin Oncol 27:4709-17. 2009
  9. ncbi Rising incidence of renal cell cancer in the United States
    W H Chow
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7240, USA
    JAMA 281:1628-31. 1999
  10. ncbi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009

Detail Information

Publications362 found, 100 shown here

  1. ncbi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with ..
  2. pmc Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:3584-90. 2009
    ..superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported.
  3. ncbi Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
    ..and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)...
  4. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
    ..data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.
  5. ncbi Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
    ..trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor-tyrosine kinase inhibitors...
  6. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  7. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
    ..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease...
  8. ncbi Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma
    Hanne Krogh Jensen
    Department of Oncology, Aarhus University Hospital, 8000 Aarhus C, Denmark
    J Clin Oncol 27:4709-17. 2009
    We have previously demonstrated a significant negative impact of intratumoral neutrophils in metastatic renal cell carcinoma. This study assessed intratumoral neutrophils in localized clear cell renal cell carcinoma (RCC).
  9. ncbi Rising incidence of renal cell cancer in the United States
    W H Chow
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7240, USA
    JAMA 281:1628-31. 1999
    Clinical surveys have revealed that incidental detection of renal cell carcinoma is rising because of increased use of imaging procedures.
  10. ncbi Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study
    Daniel Y C Heng
    FRCPC, Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    J Clin Oncol 27:5794-9. 2009
    There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF) -targeted therapy.
  11. ncbi Renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Lancet 373:1119-32. 2009
    Considerable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease...
  12. ncbi Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 356:115-24. 2007
    ..Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted...
  13. ncbi Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
    Jennifer S Ko
    Department of Immunology, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
    Clin Cancer Res 15:2148-57. 2009
    Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived suppressor cells (MDSC) represent one mechanism by which tumors induce T-cell suppression...
  14. ncbi Searching for the hereditary causes of renal-cell carcinoma
    Christian P Pavlovich
    Johns Hopkins Bayview Medical Center, Brady Urological Institute, A 345, 4940 Eastern Ave, Baltimore, Maryland 21224, USA
    Nat Rev Cancer 4:381-93. 2004
  15. ncbi Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 28:2144-50. 2010
    A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report overall survival (OS) data.
  16. pmc Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 28:2137-43. 2010
    Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC...
  17. ncbi HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity
    Huafeng Zhang
    Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Cancer Cell 11:407-20. 2007
    ..We demonstrate that transcription of the gene encoding the coactivator PGC-1beta is C-MYC dependent and that loss of PGC-1beta expression is a major factor contributing to reduced respiration in VHL-deficient renal carcinoma cells...
  18. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    Inhibitors of TORC1 have been shown to be active in patients with metastatic renal cell carcinoma (RCC)...
  19. pmc Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer...
  20. ncbi Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma
    Gerben Duns
    Departments of Genetics and Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
    Cancer Res 70:4287-91. 2010
    Sporadic clear cell renal cell carcinoma (cRCC) is genetically characterized by the recurrent loss of the short arm of chromosome 3, with a hotspot for copy number loss in the 3p21 region...
  21. ncbi MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens
    Lihong Weng
    Department of Pathology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
    J Pathol 222:41-51. 2010
    b>Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality...
  22. ncbi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
    ..potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib.
  23. pmc Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma
    Huiqing Liu
    BioMaPS Institute, Rutgers University, Piscataway, NJ 08854, USA
    BMC Syst Biol 4:51. 2010
    ..Putative mRNA targets of microRNA identified from seed sequence matches are available in many databases. However, such matches have a high false positive rate and cannot identify tissue specificity of regulation...
  24. pmc Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes
    Paulo C Rodriguez
    Department of Microbiology, Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Cancer Res 69:1553-60. 2009
    ..suppressor cells (MDSC) producing arginase I are increased in the peripheral blood of patients with renal cell carcinoma (RCC)...
  25. ncbi Sunitinib: from rational design to clinical efficacy
    Laura Q M Chow
    Department of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Clin Oncol 25:884-96. 2007
    ..and breast cancers in phase II studies, whereas definitive efficacy has been demonstrated in advanced renal cell carcinoma and in imatinib-refractory GISTs, leading to US Food and Drug Administration approval of sunitinib for ..
  26. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with ..
  27. pmc Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma
    Jinliang Xing
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 100:1104-12. 2008
    ..b>Renal cell carcinoma accounts for 85% of all renal cancers...
  28. ncbi Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response.
  29. ncbi Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma
    Takeo Nomura
    Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Urol 178:292-300. 2007
    ..In the current study we investigated the direct role of beta2-microglobulin in the regulation of human renal cell carcinoma cell growth and the possible apoptotic inducing effect of blocking the beta2-microglobulin signaling ..
  30. ncbi Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma
    Yoshio Ohno
    Department of Urology, Tokyo Medical University, Tokyo, Japan
    J Urol 184:873-8. 2010
    We investigated the prognostic significance of the neutrophil-to-lymphocyte ratio to predict recurrence in patients with nonmetastatic renal cell carcinoma.
  31. pmc Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 31:1805-12. 2010
    ..single-nucleotide polymorphisms (SNPs) in microRNAs (miRNAs)-related genes on survival and recurrence among renal cell carcinoma (RCC) patients. During a median follow-up of 21...
  32. ncbi Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
    Ian P M Tomlinson
    Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44, Lincoln s Inn Fields, London WC2A 3PX, UK
    Nat Genet 30:406-10. 2002
    ..We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6)...
  33. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  34. ncbi Rising incidence of small renal masses: a need to reassess treatment effect
    John M Hollingsworth
    Michigan Urology Center, University of Michigan, Ann Arbor, MI, USA
    J Natl Cancer Inst 98:1331-4. 2006
    ..The fact that increased detection and treatment of small tumors is not reducing mortality argues for a reassessment of the current treatment paradigm...
  35. ncbi Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
    Nicolette K Janzen
    Department of Urology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, CHS 66 118, Los Angeles, CA 90095 1738, USA
    Urol Clin North Am 30:843-52. 2003
    ..Factors including patient comorbidities and patient willingness to pursue aggressive management in the event of recurrence may alter the follow-up for each individual...
  36. ncbi Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 27:612-24. 2003
    ..compare cancer-specific survival and to examine associations with outcome among the histologic subtypes of renal cell carcinoma (RCC)...
  37. ncbi The epidemiology of renal cell carcinoma
    Loren Lipworth
    International Epidemiology Institute, 1455 Research Boulevard, Rockville, MD 20850, USA
    J Urol 176:2353-8. 2006
    ..We identified and examined risk factors for renal cell cancer, some of which may explain in part the trends of steadily increasing incidence rates, particularly in black Americans...
  38. ncbi Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    Metastatic renal cell carcinoma (RCC) has a poor prognosis and an unpredictable course. To date, there are no molecular markers which can reliably predict RCC outcome...
  39. pmc Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma
    Yohei Horikawa
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7956-62. 2008
    ..Compelling evidence has shown that miRNAs are involved in cancer initiation and progression. We hypothesized that genetic variations of the miRNA machinery genes could be associated with the risk of renal cell carcinoma.
  40. ncbi Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells
    Yong Zhong
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China
    Cancer Lett 299:150-60. 2010
    ..In this study, we sought to enrich CSCs from the renal cell carcinoma (RCC) cell line SK-RC-42 using the sphere culture system and characterize their immunophenotype...
  41. ncbi Impact of immune parameters on long-term survival in metastatic renal cell carcinoma
    Frede Donskov
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 24:1997-2005. 2006
    The purpose of this study was to evaluate the impact of immunologic prognostic factors in combination with established clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC).
  42. pmc Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram
    Alexander Kutikov
    Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA
    J Clin Oncol 28:311-7. 2010
    Many patients with localized node-negative renal cell carcinoma (RCC) are elderly with competing comorbidities. Their overall survival benefit after surgical treatment is unknown...
  43. pmc Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma
    Sebastien Le Jan
    INSERM U36, College de France, Paris
    Am J Pathol 162:1521-8. 2003
    ..We observed particularly high levels of ANGPTL4 mRNA in tumor cells of conventional renal cell carcinoma. Other benign and malignant renal tumor cells do not produce ANGPTL4 mRNA...
  44. ncbi Overexpression of the myc target gene Mina53 in advanced renal cell carcinoma
    Hironori Ishizaki
    Department of Pathology, Kurume University School of Medicine, Kurume, Japan
    Pathol Int 57:672-80. 2007
    ..study was to examined Mina53 expression and its relationship to clinicopathological parameters in human renal cell carcinoma (RCC)...
  45. pmc Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells
    Hong Xin
    Divisions of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Cancer Res 69:2506-13. 2009
    ..is used as an antiangiogenic agent for the treatment of several types of cancer, including metastatic renal cell carcinoma (RCC). Sunitinib was shown to positively change the immunosuppressive phenotype in RCC patients...
  46. ncbi Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique
    Clizia Chinello
    Department of Experimental Medicine, University of Milano Bicocca, Monza, Italy
    Urology 75:842-7. 2010
    ..related diagnostic markers that are able to better discriminate healthy subjects from patients affected by renal cell carcinoma (ccRCC). Renal cell carcinoma is the most common malignancy of the kidney...
  47. pmc FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma
    Virginia E Kwitkowski
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Oncologist 15:428-35. 2010
    ..Administration (FDA)'s approval of temsirolimus (Torisel), on May 30, 2007, for the treatment of advanced renal cell carcinoma (RCC). Information provided includes regulatory history, study design, study results, and literature review...
  48. ncbi Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure
    Pascal Hajj
    Department of Urology, Bicetre University Hospital, Universite Paris Sud, Le Kremlin Bicetre, France
    Urology 74:631-4. 2009
    To study the prevalence and the characteristics of renal cell carcinoma (RCC) in patients with autosomal dominant polycystic kidney disease (ADPKD) in our series.
  49. ncbi HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability
    Jennifer S Isaacs
    Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Cell 8:143-53. 2005
    ..Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels...
  50. ncbi Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma
    Augusto C Ochoa
    Stanley S Scott Cancer Center and Department of Pediatrics, Louisiana State University Health Sciences Center, 533 Bolivar Street, New Orleans, LA 70112, USA
    Clin Cancer Res 13:721s-726s. 2007
    ..increase in MDSC could explain the molecular alterations and dysfunction found in T cells of patients with renal cell carcinoma (RCC)...
  51. ncbi Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity
    O Nakano
    Department of Pathology, Tohoku University Graduate School of Medical Science, Sendai 980-8575, Japan
    Cancer Res 61:5132-6. 2001
    ..analyzed the biological significance of tumor-infiltrating lymphocytes in 221 patients with renal cell carcinoma without preoperative treatments...
  52. ncbi Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
    Kiran Gupta
    Abt Associates Inc, HERQuLES, 181 Spring Street, Lexington, MA 02421, United States
    Cancer Treat Rev 34:193-205. 2008
    b>Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25-30% of patients present with metastatic disease at time of diagnosis...
  53. ncbi Sorafenib for the treatment of advanced renal cell carcinoma
    Robert C Kane
    Division of Drug Oncology Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0004, USA
    Clin Cancer Res 12:7271-8. 2006
    ..S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar, BAY43-9006), a new small-molecule, oral, multi-kinase inhibitor for the treatment of patients with advanced renal cell carcinoma (RCC).
  54. ncbi Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
    L Schmidt
    Intramural Research Support Program, SAIC Frederick, MD, USA
    Nat Genet 16:68-73. 1997
    ..The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas...
  55. ncbi C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Cancer 110:1241-7. 2007
    C-reactive protein (CRP) represents a promising prognostic variable in patients with sporadic renal cell carcinoma (RCC)...
  56. ncbi Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
    Dorothy A White
    Memorial Sloan Kettering Cancer Center, Pulmonary Medicine, New York, NY 10021, USA
    Am J Respir Crit Care Med 182:396-403. 2010
    ..Noninfectious pneumonitis is a known class effect of mammalian target of rapamycin (mTOR) inhibitors...
  57. ncbi Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
    Sergei Kusmartsev
    Department of Urology, College of Medicine, University of Florida, Gainesville, Florida 32610 0247, USA
    Clin Cancer Res 14:8270-8. 2008
    ..immunosuppression remains a significant obstacle that limits the efficacy of biological therapy for renal cell carcinoma. Here we evaluate the role of CD33 myeloid-derived suppressor cells (MDSC) in the regulation of T-cell ..
  58. ncbi Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:7388-93. 2007
    ..Here, we evaluated the significance of HIF-1 alpha in renal cell carcinoma (RCC).
  59. ncbi Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    Brian I Rini
    University of California San Francisco Comprehensive Cancer Center, CA, USA
    J Clin Oncol 23:1028-43. 2005
    To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic RCC.
  60. ncbi The von Hippel-Lindau tumor suppressor gene and kidney cancer
    William G Kaelin
    Howard Hughes Medical Institute, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:6290S-5S. 2004
    ..basis of these and other data, VHL appears to be a critical gatekeeper with respect to the development of renal cell carcinoma. The VHL gene product, pVHL, is the substrate recognition module of an E3 ubiquitin ligase that targets the ..
  61. ncbi Identification of novel target genes by an epigenetic reactivation screen of renal cancer
    Inmaculada Ibanez de Caceres
    Departments of Surgical Oncology and Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 66:5021-8. 2006
    ....
  62. ncbi Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at UCLA, Center for Health Sciences, Los Angeles, CA 90025 1738, USA
    J Clin Oncol 27:746-53. 2009
    The majority of cytogenetic studies in renal cell carcinoma (RCC) have been impaired by small sample size, retrospective character, and lack of a survival end point...
  63. pmc High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
    Jacob A Klapper
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 113:293-301. 2008
    The treatment of metastatic renal cell carcinoma (RCC) with high-dose interleukin-2 (HD IL-2) has resulted in durable tumor regression in a minority of patients...
  64. ncbi Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma
    Kyle A Furge
    Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan, USA
    Cancer Res 67:3171-6. 2007
    Papillary renal cell carcinoma (RCC) represents 10% to 15% of adult renal neoplasms; however, the molecular genetic events that are associated with the development and progression of sporadic papillary RCC remain largely unclear...
  65. ncbi Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience
    Jean Jacques Patard
    Department of Urology, Rennes University Hospital, Rennes, France
    J Clin Oncol 23:2763-71. 2005
    To analyze to what extent histologic subtype is of prognostic importance in renal cell carcinoma based on a large, international, multicenter experience.
  66. ncbi Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma
    Gursah Kats-Ugurlu
    Department of Pathology, Radboud University, Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    J Pathol 219:287-93. 2009
    ..Here we tested whether this process has clinical relevance for clear cell renal cell carcinoma (ccRCC), a prototype tumour in the sense of high constitutive VEGF-A expression...
  67. ncbi Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings
    Maryellen R M Sun
    Department of Radiology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    Radiology 250:793-802. 2009
    ....
  68. ncbi Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: association with vascular endothelial growth factors A to D immunohistochemistry
    Takahisa Iwata
    Department of Urology, Nagasaki University School of Medicine, Nagasaki, Japan
    Urology 71:749-54. 2008
    ..However, little is known about the pathologic roles of lymphangiogenesis in renal cell carcinoma (RCC)...
  69. pmc Pathway signature and cellular differentiation in clear cell renal cell carcinoma
    Han W Tun
    Department of Hematology Oncology, Mayo Clinic, Jacksonville, Florida, United States of America
    PLoS ONE 5:e10696. 2010
    Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. The purpose of this study is to define a biological pathway signature and a cellular differentiation program in ccRCC.
  70. ncbi Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer
    Seiichiro Ozono
    Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
    Jpn J Clin Oncol 34:82-5. 2004
    This study was conducted to examine the natural history of renal cell carcinoma (RCC).
  71. ncbi Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma
    Tao Zhang
    Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China
    Cancer Lett 283:59-67. 2009
    The lack of effective anti-tumor therapy for renal cell carcinoma (RCC) has stimulated the search for novel target whose inhibition could block tumorigenesis...
  72. ncbi Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma
    Yukihiko Kato
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 13:4538-46. 2007
    ..interleukin 2 (IL-2) is a Food and Drug Administration-approved regimen for patients with metastatic renal cell carcinoma. However, the toxicity and limited clinical benefit associated with IL-2 has hampered its use...
  73. ncbi Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma
    Xavier Leroy
    Department of Pathology, University Hospital, CHRU and Lille II University, Lille, France
    Histopathology 56:180-7. 2010
    ..The aim was to analyse the expression of endocan or endothelial cell-specific molecule-1, which is a proteoglycan up-regulated in presence of pro-angiogenic factors...
  74. ncbi Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia
    Peter Schraml
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Mod Pathol 22:31-6. 2009
    Renal cysts and clear cell renal cell carcinoma are common clinical manifestations of people with germ-line mutations of the von Hippel-Lindau tumor suppressor gene, VHL...
  75. ncbi Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma
    Davit Mosashvilli
    Department of Urology, University Hospital Bonn, Bonn, Germany
    Cancer Sci 101:2664-9. 2010
    ..histone H3 acetylation [H3Ac] and total histone H4 acetylation [H4Ac]) were determined in patients with renal cell carcinoma (RCC) using immunohistochemistry in a tissue micro array with 193 RCC and 10 oncocytoma specimens...
  76. ncbi CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma
    Linhui Wang
    The Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, PR China
    Oncol Rep 22:1333-9. 2009
    b>Renal cell carcinoma (RCC) shows organ-specific metastasis...
  77. ncbi Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B
    Balaji Krishnamachary
    Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 66:2725-31. 2006
    ..Thus, HIF-1 contributes to the epithelial-mesenchymal transition in VHL-null RCC by indirect repression of E-cadherin...
  78. ncbi Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Edit Remak
    Health Care Analytics, United BioSource Corp, 20 Bloomsbury Square, London WC1A 2NS, United Kingdom
    J Clin Oncol 26:3995-4000. 2008
    To assess the cost effectiveness and cost utility of sunitinib malate as a first-line treatment in metastatic renal cell carcinoma (mRCC) compared with interferon-alfa (IFN-alpha) and interleukin-2 (IL-2) from a US societal perspective.
  79. ncbi Gene signatures of progression and metastasis in renal cell cancer
    Jon Jones
    Beth Israel Deaconess Medical Center Genomics Center and Dana Farber Harvard Cancer Center Proteomics Core, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:5730-9. 2005
    ..To address the progression, metastasis, and clinical heterogeneity of renal cell cancer (RCC)...
  80. pmc Annexin II represents metastatic potential in clear-cell renal cell carcinoma
    Y Ohno
    Department of Urology, Tokyo Medical University, Tokyo, Japan
    Br J Cancer 101:287-94. 2009
    ..The purpose of this study was to assess ANX2 expression in clear-cell (cc) renal cell carcinoma (RCC).
  81. ncbi Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 106:566-75. 2006
    ..COX-2 is expressed in the majority of renal cell carcinoma (RCC) tumors and correlates with stage, grade, and microvessel density...
  82. ncbi Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ..carbonic anhydrase IX (CAIX) expression and histological features for predicting the outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy.
  83. ncbi The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis
    Essam M Elsamman
    Department of Urology and Department of Anatomy and Cell Biology, The University of Tokushima Graduate School Institute of Health Biosciences, Tokushima, Japan
    BJU Int 98:668-73. 2006
    To analyse the gene expression level of prostate stem cell antigen (PSCA) in human clear cell renal cell carcinoma (CC-RCC) and its relationship with conventional clinicopathological manifestations, to evaluate its prognostic value for ..
  84. ncbi Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma
    Dorina Veliceasa
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    FEBS J 274:6365-77. 2007
    Angiogenic switch in renal cell carcinoma (RCC) is attributed to the inactivation of the von Hippel-Lindau tumor suppressor, stabilization of hypoxia inducible factor-1 transcription factor and increased vascular endothelial growth factor...
  85. pmc The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis
    K Dreijerink
    Laboratory of Immunobiology and Intramural Research Support Program, Science Applications International Corporation, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 98:7504-9. 2001
    ..Mutant RASSF1A had reduced growth suppression activity significantly. These data suggest that RASSF1A is the candidate renal TSG gene for the 3p21.3 region...
  86. pmc Tumor-to-tumor metastasis: Renal cell carcinoma metastatic to papillary carcinoma of thyroid-report of a case and review of the literature
    Olga L Bohn
    Department of Pathology, MetroHealth Medical Center Case Western Reserve University, Cleveland, OH 44109, USA
    Head Neck Pathol 3:327-30. 2009
    Metastatic disease to thyroid gland is a rare event. Although renal cell carcinoma (RCC) has been reported to metastasize the thyroid gland, metastatic RCC to a thyroid neoplasm is very unusual...
  87. ncbi von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 180:860-5; discussion 865-6. 2008
    The von Hippel-Lindau (VHL) gene is often inactivated (by mutation or promoter hypermethylation) in renal cell carcinoma but the relation to therapeutic outcome is unclear.
  88. pmc The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth
    Valérian Dormoy
    INSERM U682, Section of Renal Cancer and Renal Physiopathology, University of Strasbourg, School of Medicine, Strasbourg, 67085 France
    Mol Cancer 8:123. 2009
    Human clear cell renal cell carcinoma (CRCC) remains resistant to therapies. Recent advances in Hypoxia Inducible Factors (HIF) molecular network led to targeted therapies, but unfortunately with only limited clinical significance...
  89. ncbi Differentiation of subtypes of renal cell carcinoma on helical CT scans
    Jeong Kon Kim
    Department of Radiology, Asan Medical Center, University of Ulsan, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, South Korea
    AJR Am J Roentgenol 178:1499-506. 2002
    The purpose of our study was to differentiate subtypes of renal cell carcinoma on helical CT scans.
  90. ncbi Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    Walter M Stadler
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Cancer 116:1272-80. 2010
    The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval.
  91. ncbi Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival
    Yasuyoshi Miyata
    Department of Urology, Nagasaki University School of Medicine, Japan
    Clin Cancer Res 9:1741-9. 2003
    ..However, the relationships between COX-2 expression and these biological processes, clinicopathological features, and survival rate in patients with renal cell carcinoma are not clear.
  92. pmc Tumor size is associated with malignant potential in renal cell carcinoma cases
    R Houston Thompson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 181:2033-6. 2009
    ..We evaluated our experience with renal cortical tumors to determine whether tumor size is associated with malignant histology and/or nuclear grade...
  93. ncbi Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients
    Sei Naito
    Department of Urology, Yamagata University, Yamagata 951 8510, Japan
    Eur Urol 57:317-25. 2010
    Incidence rate of renal cell carcinoma (RCC) differs among countries. The rates of Asian countries are lower than those of countries in North America or Europe but are exceptionally high in Japanese males...
  94. ncbi Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
    Giovanni C Cesana
    Tumor Immunology Laboratory, Department of Surgery and Biostatistics, Columbia University Medical Center, New York, NY 10032, USA
    J Clin Oncol 24:1169-77. 2006
    To characterize the number and functional status of CD4+CD25+ regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolus interleukin-2 (IL-2).
  95. ncbi Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma
    M A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 29:5724-8. 2010
    The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence...
  96. ncbi Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:127-31. 2008
    ..are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated.
  97. ncbi Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells
    Longxin Wang
    Department of Urology, Xijing Hospital, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi an, Shaanxi Province, China
    Clin Cancer Res 16:164-73. 2010
    ....
  98. ncbi Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study
    Zhong Jiang
    University of Massachusetts Medical Center, Department of Pathology, Worcester, MA, USA
    Lancet Oncol 7:556-64. 2006
    ..We aimed to investigate whether IMP3, an oncofetal RNA-binding protein, can be used as a biomarker to predict metastasis and prognosis of renal-cell carcinoma...
  99. ncbi Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
    ..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
  100. ncbi Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    James H Finke
    Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 14:6674-82. 2008
    Immune dysfunction is well documented in renal cell carcinoma (RCC) patients and likely contributes to tumor evasion...
  101. ncbi Clinical significance of Galectin-3 in clear cell renal cell carcinoma
    Manabu Sakaki
    Department of Urology, Institute of Health Biosciences, University of Tokushima Graduated School, Tokushima, Japan
    J Med Invest 57:152-7. 2010
    ..In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological ..

Research Grants74

  1. Sutureless Laparoscopic Partial Nephrectomy Using Laser Tissue Welding: Preclinic
    Yasmin Wadia; Fiscal Year: 2013
    ..and nephron-sparing surgery substitutes for radical nephrectomy in appropriately selected patients with renal cell carcinoma. Laparoscopic partial nephrectomy (LPN) has demonstrated excellent outcomes in terms of oncologic control, ..
  2. Genistein, microRNAs and kidney cancer
    Rajvir Dahiya; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Background: Renal cell carcinoma (RCC) is one of the most common malignancies among our Veterans...
  3. Role of Diabetes in Development of Renal Cell Carcinoma
    SAMY LEWIZ HABIB; Fiscal Year: 2013
    ..Our preliminary studies show that incubation of rat renal proximal tubular cells (the cell origin of renal cell carcinoma) in high glucose results in increased reactive oxygen species (ROS) enhanced tuberin phosphorylation and ..
  4. Systemic AA Amyloidosis Inhibitors
    ALAN D SNOW; Fiscal Year: 2010
    ..ankylosing spondylitis, inflammatory bowl disease, tuberculosis, leprosy, Hodgkin's disease, renal cell carcinoma, and Familial Mediterranean Fever...
  5. Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
    Othon Iliopoulos; Fiscal Year: 2012
    The incidence of renal cell carcinoma (RCC) in United States has been projected to reach 56,000 cases/year in 2007 and has been rising since 1970 for both men and women and for whites as well as blacks...
  6. PAX2 gene targets, binding sites and function
    Patrick D Brophy; Fiscal Year: 2010
    ..of Pax2 is found in human and mouse PKD, dysplastic and cystic disease and also is associated with renal cell carcinoma and the Wilms Tumor...
  7. HIF-2alpha mediated mitophagy and lipogenesis in clear cell renal cell carcinoma
    Bo Qiu; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Clear cell renal cell carcinoma (ccRCC) is the most common renal malignancy worldwide...
  8. Effect of MIP-1 delta on Osteoclast Development and Pathological Bone Resorption
    Scott L Kominsky; Fiscal Year: 2010
    ..Interestingly, we recently found levels of the MIP family member MIP-1d to be significantly elevated in renal cell carcinoma bone metastasis (RBM), which frequently causes excessive bone destruction...
  9. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    JOSEPH VINCENT BONVENTRE; Fiscal Year: 2013
    ..in various states characterized by epithelial cell dedifferentiation: ischemia, toxic renal injury, and renal cell carcinoma. We have cloned, and generated monoclonal and polyclonal antibodies to, the human, mouse, pig, dog, ..
  10. Mechanism of Gene Repression in the Kidney
    Sanjeevkumar R Patel; Fiscal Year: 2013
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, including renal cell carcinoma, polycystic kidney disease, Wilms'tumor, and prostate carcinoma...
  11. Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal c
    JOHN THOMAS LEPPERT; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC, kidney cancer) is one of the most commonly diagnosed cancers and is associated with significant mortality...
  12. Novel multivalent/multifunctional agents derived from a humanized anti-insulin-li
    Thomas M Cardillo; Fiscal Year: 2010
    ..One of the most challenging forms of this type of cancer is metastatic renal cell carcinoma (RCC). It has resisted attempts of curative radiotherapy and chemotherapy...
  13. Wnt antagonist genes in kidney tumor progression and metastasis
    Rajvir Dahiya; Fiscal Year: 2012
    ..whether inactivation of Wnt antagonist genes is involved in the progression and metastasis of human renal cell carcinoma. Based on the preliminary data, we have screened several Wnt antagonist genes and have identified six genes ..
  14. Regultion of p53 Deubiquitination
    Zhenkun Lou; Fiscal Year: 2013
    ..Finally, we found loss of USP10 expression in high percentage of renal cell carcinoma cases...
  15. Sphingolipid Signaling in Endothelial Responses to Injury
    TERESA SANCHEZ GARCIA-VAO; Fiscal Year: 2013
    ..in the Matrigel model and in a model of tumor angiogenesis, involving subcutaneous injection of the murine renal cell carcinoma line, RENCA, into syngeneic wild type, S1p2r , S1p2r-/- and Pten mice...
  16. Predictive Markers in Metastatic Renal Cancer
    Phillip G Febbo; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Metastatic renal cell carcinoma (RCC) is a dismal disease, with nearly uniform resistance to radiotherapy, chemotherapy and immunotherapy...
  17. Pathway Specific Imaging in VHL Deficient Renal Cancer
    PANKAJ K SETH; Fiscal Year: 2013
    ..is that administration of DCA will result in decreased lactate formation in an orthotopic mouse model of renal cell carcinoma, and that this "pharmacodynamic" measurement will correlate with decreased tumor burden in this model...
  18. Germline KLLN Alterations in PTEN Mutation Negative Cowden Syndrome
    EMILY ALISON NIZIALEK; Fiscal Year: 2013
    ..KLLN hypermethylation had an increased risk, compared to PTEN mutation positive patients, for developing renal cell carcinoma and breast cancer...
  19. Technology and Endothelial Biology of Kidney Injury Molecule-1
    Vishal S Vaidya; Fiscal Year: 2010
    ..and can be quantitated, by an ELISA assay, in the urine of rodents and patients with kidney injury or renal cell carcinoma. An important feature common to repair of the tissue after injury (e.g...
  20. TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
    Thomas S Griffith; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): This year in the U.S. ~40,000 new cases of renal cell carcinoma (RCC) will be diagnosed and >13,000 deaths are expected from RCC...
  21. REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCER
    Debabrata Mukhopadhyay; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Most of the cases, the clear-cell renal cell carcinoma (RCC) express strikingly elevated baseline levels of vascular permeability factor also known as vascular endothelial growth factor (VEGF) ..
  22. Investigation of the Role of BAP1 in Normal and Malignant Hematopoiesis
    LINDSAY MARIE LAFAVE; Fiscal Year: 2013
    ..other cancer contexts where BAP1 mutations are quite prevalent, such as uveal melanoma, mesothelioma, and renal cell carcinoma. Further, we will establish novel MDS models for future testing of novel therapeutic agents in subsequent ..
  23. 124I-cG250 ImmunoPET Imaging of Sunitinib Treatment Response in Renal Cell Cancer
    STEVEN MARK LARSON; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) is the most common malignancy of the kidney, accounting for more than 58,000 new diagnoses of cancer and 13,000 cancer deaths in the United States during 2010...
  24. The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 Immunotherapy
    Paul M Sondel; Fiscal Year: 2013
    ..genotype data, can identify patients more likely to respond to: a) single agent mAb therapy for lymphoma, b) single agent IL2 treatment for renal cell carcinoma (RCC), and c) mAb + cytokine (IL2 + GM-CSF) therapy for neuroblastoma (NBL).
  25. Expression profiling of renal cell carcinoma utilizing tissue from CALGB 90206
    Hyung L Kim; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): One third of patients newly diagnosed with renal cell carcinoma (RCC) have metastatic disease...
  26. Bifunctional T cell receptor based immunotherapeutics
    Hing C Wong; Fiscal Year: 2011
    ..trial to evaluate the efficacy and safety of ALT-801 in subjects with refractory metastatic melanoma, renal cell carcinoma, head and neck cancer and prostate cancer at the MTD dose level...
  27. Models to predict prognosis and benefit from adjuvant therapy in renal cell carci
    Harriet M Kluger; Fiscal Year: 2013
    ..endothelial cells, and develop models to predict clinical benefit from adjuvant sorafenib and sunitinib for renal cell carcinoma (RCC), as well as models to predict prognosis in untreated patients...
  28. The Role of Planar Cell Polarity Signals in Shaping Kidney Tubules
    RACHEL KATHERINE MILLER; Fiscal Year: 2013
    ..has been linked to developmental pathologies such as Wilms tumor and cystic diseases, as well as with renal cell carcinoma. Recent studies from our group and others indicate that canonical (?-catenin- mediated) Wnt signaling is ..
  29. Targeting Novel T Cell Antigens on Renal Cell Carcinoma
    Scott S Tykodi; Fiscal Year: 2010
    Metastatic renal cell carcinoma (RCC) is poorly responsive to most conventional cancer therapy, but regression of metastatic RCC is seen in 10-20% of patients treated with non-specific immunotherapies such as interleukin-2 or interferon-(..
  30. High-throughput screen for specific small-molecule inhibitors of HIF-2A activity
    Mei Yee Koh; Fiscal Year: 2013
    ..HIF-2[unreadable] is an important driver of tumor morbidity in renal cell carcinoma (RCC), neuroblastoma, glioblastoma (GBM) and non small cell lung cancer (NSCLC)...
  31. Defining the effects of bortezomib on NK cell activation in cancer
    Anil Shanker; Fiscal Year: 2013
    ..A similar role of combined CD8+ T cells and NK cells was also observed by us in the rejection of mouse renal cell carcinoma Renca and by others in the control of mammary, bladder and intraperitoneal mesenchymal tumors...
  32. Free-Breathing Perfusion MRI of the Abdomen with Predictive Motion Correction
    H Michael Gach; Fiscal Year: 2013
    ..Diagnostic imaging serves a key role in detecting and monitoring renal diseases including renal cell carcinoma (RCC)...
  33. Image-guided combination therapy: noninvasive assessment of delivery and response
    Susanta K Sarkar; Fiscal Year: 2013
    ..inhibitor, pazopanib, is one of the promising AAT drugs and has been recently approved for advanced renal cell carcinoma and is currently in clinical trials for combination therapy of multiple tumor types...
  34. Promoting Tumor Immunity by Cross-Linking B7-DC
    Larry R Pease; Fiscal Year: 2013
    ..Treatment of animals with the immune modulator prevented the outgrowth of melanoma, renal cell carcinoma, lymphoma, leukemia, and breast cancer, demonstrating the potential application of this reagent to the ..
  35. Enhancing renal cell carcinoma response to IL-2 with the HDAC inhibitor SNDX-275
    Roberto Pili; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): High dose interleukin 2 (IL-2) is an approved regimen for metastatic renal cell carcinoma (RCC). Unfortunately, the response rate is modest and only few patients achieve durable remission...
  36. Role of fumarate hydratase in renal hypoxia and tumorigenesis
    Sunil Sudarshan; Fiscal Year: 2013
    ..enable the candidate to become an independent physician-scientist whose goal is to further understanding of renal cell carcinoma through the study of inherited forms of kidney cancer...
  37. VHL tumor suppressor gene and the initiation of renal cell carcinoma
    Tien Hsu; Fiscal Year: 2013
    ..Up to 70% of the carriers of germ line VHL mutations develop renal cell carcinoma of the clear-cell type (ccRCC)...
  38. Cadherin-regulated apoptosis and survival signaling in epithelial cells
    STEEN HENNING HANSEN; Fiscal Year: 2013
    ..Loss of E-cadherin expression occurs in familial cancer syndromes and sporadic cancer, with renal cell carcinoma serving a prominent example of both...
  39. Elimination of Immature Myeloid Cells
    Johannes Vieweg; Fiscal Year: 2009
    ..and promising strategy to eliminate immunosuppressive immature myeloid suppressor cells (ImC) in metastatic renal cell carcinoma patients (RCC)...
  40. Pooled genome-wide analysis of kidney cancer risk
    Ghislaine Scelo; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) is the 8th most common cancer in the US and the 10th most common form of cancer death, with over 34,000 cases and 12,000 deaths each year...
  41. Metabolomic discovery and validation of urinary biomarkers for kidney cancer
    Robert H Weiss; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Kidney cancer (also known as renal cell carcinoma [RCC]) is diagnosed in 36,000 patients and is the cause of death of 11-13,000 individuals yearly in the US;unfortunately (and for unknown reasons), ..
  42. Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
    DANIEL CHANG CHO; Fiscal Year: 2013
    ..Cho has chosen to focus his research career on developing novel therapies for the treatment of renal cell carcinoma (RCC)...
  43. Interferon-induced SLFNs and tumorigenesis
    Leonidas C Platanias; Fiscal Year: 2013
    ..For that purpose malignant melanoma or renal cell carcinoma (RCC) mouse models will be established using mice with the elektra phenotype (Slfn2eka/eka) or Slfn1 or ..
  44. Characterization and therapeutic targeting of HIF in LKB1 - deficient lung cancer
    William Y Kim; Fiscal Year: 2013
    ..HIF2 has been shown to be a bona fide oncogene in renal cell carcinoma (RCC) and downstream mediators of HIF2 signaling are the relevant therapeutic targets that have resulted in ..
  45. Identifying a Hypoxia Inducible Factor target profile in Renal Cell Carcinoma tum
    Alexandra Arreola; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) is a highly prevalent malignancy with a high mortality rate...
  46. Enhancing Translational Science via Prospective Investigation
    WENDY K RATHMELL; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Renal cell carcinoma is a cancer with major unmet clinical needs for which the incidence is steadily rising, and which is increasingly becoming a multidisciplinary disease...
  47. Inhibiting VHL-positive kidney cancer
    GEORGE VICTOR THOMAS; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Patients with VHL-positive renal cell carcinoma (RCC) have very few treatment options...
  48. A research and training program for junior clinicians in treating metastatic mela
    Harriet M Kluger; Fiscal Year: 2013
    ..I am an associate professor, seeing patients with melanoma and renal cell carcinoma. I mentor junior faculty and clinical fellows and run an R-01 funded research laboratory, conducting ..
  49. Mechanism of Acquired Resistance to VEGF-R Antagonists in RCC
    Rupal S Bhatt; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Renal cell carcinoma (RCC) exhibits a period of disease stabilization in response to inhibitors of vascular endothelial growth ..
  50. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    Eugene D Kwon; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) encompasses 90% of kidney cancers and 3% of adult cancers. In the U.S. alone, more than 30,000 new cases of RCC are diagnosed and nearly 13,000 patients die from RCC annually...
  51. Novel treatment strategies for enhancing sunitinib response in renal cell cancer
    Towia A Libermann; Fiscal Year: 2013
    ..by applicant): While there has been significant progress in management of early stages of clear cell renal cell carcinoma (RCC), metastatic RCC has few effective therapeutic strategies available and a death rate close to the ..
  52. Visual Programming Tool for Integrated Gene/Protein Networks in Cancer Research
    Maciek Sasinowski; Fiscal Year: 2011
    ..development will be performed in parallel with a multidisciplinary, integrative biological study of renal cell carcinoma (RCC, or kidney cancer)...
  53. Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
    Xifeng Wu; Fiscal Year: 2013
    ..tissues, and comprehensive epidemiology data including diet, obesity, and physical activity of an ongoing renal cell carcinoma (RCC) case control study from Texas...
  54. B7-H3 in prognosis and immunotherapy of pancreatic cancer
    Xinhui Wang; Fiscal Year: 2010
    ..our own results: i) the level of B7-H3 expression in hypopharyngeal carcinoma, non-small-lung carcinoma, renal cell carcinoma and prostate carcinoma is associated with the clinical course of the disease, ii) the B7-H3-specific mAb ..
  55. Role of NFxB/HIF2a axis in renal cell carcinoma progression
    E Jason Abel; Fiscal Year: 2013
    ..His past record of achievement is exceptional, including 11 manuscripts on renal cell carcinoma (RCC)...
  56. Immunotherapy for Renal Cell Carcinoma
    Marc S Ernstoff; Fiscal Year: 2010
    Biological therapies, such as aldesleukin (IL-2), for metastatic renal cell carcinoma (mRCC) are designed to mobilize immune effector cells that recognize and destroy cancer...
  57. Chromatin organization and transcription factor targeting in cancer
    Ian J Davis; Fiscal Year: 2013
    ..between hypoxia pathway signaling and the development of cancer are nowhere more relevant than in renal cell carcinoma. Hypoxia, the reduction in oxygen content in tissues, leads to the stabilization of the transcription ..
  58. Role of Notch and Kidney Development
    Raphael Kopan; Fiscal Year: 2012
    ..cells that continue to divide and develop papillary adenomas, thought to be the precursor for papillary renal cell carcinoma (PRCC). Injury increases the frequency of cyst and papillary adenoma formation...
  59. TGF Beta receptor biology in human renal cell carcinoma
    JOHN COPLAND; Fiscal Year: 2009
    b>Renal cell carcinoma (RCC) is a major health issue. While localized disease can be cured surgically, there is no effective treatment for metastatic disease...
  60. Regulation of MDSC function and trafficking
    James H Finke; Fiscal Year: 2013
    ..immunosuppressive- and angiogenic G-MDSCs that infiltrate inflammatory murine tumors is paralleled in human renal cell carcinoma (RCC) tumors, which also accumulate mostly G-MDSCs...
  61. TAS::75 0849::TAS TOPIC 255 SELECTIVE AND POTENT INHIBITORS OF TUMOR SPECIFIC GL
    Paul Pearson; Fiscal Year: 2011
    Previously, we employed a novel, chemical synthetiC lethal screening approach in VHL-deficient renal cell carcinoma (RCC VHL-) to identify inhibitors of GLUT1, a glucose transporter critical for RCC energy metabolism and survival...
  62. Prostaglandin Receptor Regulation of Kidney Cancer
    Yehia Daaka; Fiscal Year: 2013
    ABSTRACT PROSTAGLANDIN RECEPTOR REGULATION OF KIDNEY CANCER Renal cell carcinoma is a leading cause of cancer death, and its incidence is steadily increasing at an annual rate of 2.5% across population groups...
  63. RENAL CELL CARCINOMA--ADOPTIVE IMMUNOTHERAPY
    KURT STENZEL; Fiscal Year: 1990
    The long term goal of this study is to develop successful immunotherapy for human renal cell carcinoma based on the adoptive transfer of autologous, mononuclear leukocytes (PBM) activated in a novel way (combined treatment with sodium ..
  64. RENAL CYST PATHOGENESIS IN TSC, VHL, AND ADPKD
    ELIZABETH HENSKE; Fiscal Year: 1999
    ..It is of particular interest because the cysts in VHL can progress to renal cell carcinoma. Renal cell carcinoma causes 10,000 deaths annually in the United States...
  65. Systemic AA Amyloidosis Inhibitors
    ALAN SNOW; Fiscal Year: 2004
    ..ankylosing spondylitis, inflammatory bowel diseases, tuberculosis, leprosy, Hodgkin's disease, renal cell carcinoma, and Familial Mediterranean Fever...
  66. Analysis of the Novel Kinase ROR2: A New Molecular Target in Renal Cell Carcinoma
    Tricia M Wright; Fiscal Year: 2010
    b>Renal cell carcinoma (RCC), a notoriously hard to treat solid tumor and the most common form of kidney cancer, has minimal sensitivity to traditional chemotherapy...
  67. Genetic Susceptibility Modifiers in Renal Cell Carcinoma
    Xifeng Wu; Fiscal Year: 2007
    ..Tobacco exposure is an established risk factor for renal cell carcinoma (RCC)...
  68. A Schizosaccharomyces pombe Model of Birt-Hogg-Dube Syndrome
    ELIZABETH HENSKE; Fiscal Year: 2007
    ..an autosomal dominant disorder characterized by skin hamartomas, lung cysts, spontaneous pneumothorax, and renal cell carcinoma. A germline mutation in the BHD gene was also recently found in a large kindred with dominantly inherited ..
  69. MOLECULAR-GENETIC ANALYSIS OF 3P14 GENOMIC STABILITY
    Harry Drabkin; Fiscal Year: 2006
    ..rearrangement of any protein that interacts with VHL and its function may be germane to the development of renal cell carcinoma (RCC)...
  70. Analysis of Somatic Mutations in Cancer of the Kidney
    WAYNE VEDECKIS; Fiscal Year: 2005
    ..in p53 result from tobacco smoke carcinogens), and because we have access to DNA from 1,141 newly diagnosed renal cell carcinoma cases in the INCO Central Europe Health Study (CEHS), this NCI R03 project will evaluate whether there is a ..
  71. Genetic Retargeted Human T-cells for RCC Immunotherapy
    Wayne Marasco; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Renal cell carcinoma (RCC) is the most prevalent malignancy within the kidney and the incidence is rising...
  72. CANCER SUPPRESSION AND DEVELOPMENTAL FUNCTIONS OF THE RB
    Eva Lee; Fiscal Year: 1993
    ..g. retinoblastoma, breast cancer, colon cancer, renal cell carcinoma, etc...
  73. MDA-7/IL-24 and free radicals in renal cancer therapy
    Paul Dent; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Renal Cell Carcinoma (RCC) is among the most lethal and difficult tumors to treat, particularly when disease has spread beyond the kidney and into the surrounding fascia;even intensive combinations of ..
  74. BIOLOGY OF BLADDER CANCER METASTASES
    Colin Dinney; Fiscal Year: 2000
    ..Elevated levels of bFGF have been associated with a number of malignancies, including renal cell carcinoma, breast carcinoma, and lung carcinoma...